双黄连口服液

Search documents
淅川县先进制造业开发区入选2025年河南省开发区数字化转型促进中心名单
Zhong Guo Jing Ji Wang· 2025-06-23 14:45
据悉,淅川县先进制造业开发区规划面积13.03平方公里,下辖城区工业园区和香九厚工业园区,累计 入驻企业184家。近年来,该开发区锚定数字化转型赛道,以创新驱动发展:通过绘制产业全景图谱, 全力推进汽车零部件、现代中药、新能源、新材料四大产业集群数字化升级,推动企业降本增效、创新 突破。 坚持龙头带动壮集群。聚焦主导产业,紧盯产业链图谱,持续延链补链强链,壮大产业集群。以淅减为 龙头的汽车零部件产业,关联企业86家,产品以汽车减振器为主导,形成了涵盖冲压件、旋压件、活塞 杆等八大系列上千个品种,市场占有率达20%。以福森药业为龙头的现代中医药产业,关联企业35家, 形成了集种植、研发、加工、物流等为一体的全产业链,双黄连口服液和双黄连注射液在国内市场份额 分别达到35.5%和91.6%。新能源、新材料产业,以河南福森新能源科技有限公司、河南淅川平煤三责 精密陶瓷有限公司、南阳天成新能源科技有限公司、河南晶多多新材料科技有限公司等企业为龙头,关 联企业63家,产品涉及动力电池、储能电池、碳化硅精密陶瓷、人造石墨、负极材料等,全面建成达产 后预计年产值可突破200亿元。 日前,凭借扎实的数字化建设基础与创新的转型 ...
淅川这场会,民营企业家坐“C位”
Sou Hu Cai Jing· 2025-06-19 02:52
河南日报社三农全媒体中心记者 曹国宏 通讯员 卢晋荥 "有事不撒手、无事不插手、好事不伸手、难事不放手。"6月18日,淅川县召开促进民营经济高质量发展暨优化营商环境大会。与往常会议不同,此次会 议主席台上,淅减、淅水、福森、胶联时代四个有突出贡献的本地企业家代表坐"C位";会场前排,民营企业、行业商协会代表与县处级领导并肩而坐。 此举生动诠释了淅川尊商重企的坚定决心。 "要把各级政策措施落实摆在突出位置、精准滴灌,切实把政策红利转化为民营经济的发展动力。"大会要求,全县各级各部门要把准大局大势,坚定信心 谋发展;落实政策措施,打造发展新高地;持续创优环境,政企同心干实业,开创民营经济高质量发展新局面。 会场内,承诺铿锵有力:"实施'有诉即办'提升行动,确保企业诉求'有求必应、有问必答'!""全面收集企业用工、融资等方面问题,分层次推进解决,为 企业发展扫清障碍!"……一句句务实表态,彰显着促进民营经济发展的态度、优化营商环境的决心。 淅减智能化装配生产车间 卢晋荥 摄 近年来,淅川县始终将发展壮大民营经济摆在突出位置。该县坚持维护公平竞争市场秩序,锚定实体经济主攻方向,聚焦制造业高质量发展,大力招商引 资,积 ...
太龙药业(600222):国资赋能+集采放量,中药CRO打开第二曲线
Great Wall Securities· 2025-06-13 11:45
证券研究报告 | 公司深度报告 2025 年 06 月 13 日 太龙药业(600222.SH) 国资赋能+集采放量,中药 CRO 打开第二曲线 | 财务指标 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业收入(百万元) | 2,070 | 1,941 | 2,132 | 2,348 | 2,583 | | 增长率 yoy(%) | 5.6 | -6.2 | 9.8 | 10.1 | 10.0 | | 归母净利润(百万元) | 44 | 51 | 61 | 85 | 116 | | 增长率 yoy(%) | 160.3 | 16.0 | 21.5 | 38.4 | 36.5 | | ROE(%) | 2.8 | 3.3 | 3.9 | 5.0 | 6.4 | | EPS 最新摊薄(元) | 0.08 | 0.09 | 0.11 | 0.15 | 0.20 | | P/E(倍) | 80.9 | 69.7 | 57.4 | 41.5 | 30.4 | | P/B(倍) | 2.2 | 2.2 ...
珍宝岛拟4.9亿元收购贵州神农谷49%股权 加速完善中药产业链总资产增至128.7亿元
Chang Jiang Shang Bao· 2025-05-29 23:47
Core Viewpoint - Zhenbaodao is accelerating the improvement of its traditional Chinese medicine industry chain layout through the acquisition of a 49% stake in Guizhou Shennong Valley, which will become a wholly-owned subsidiary of its subsidiary Bozhou Trading Center [1] Group 1: Acquisition Details - The acquisition amount is 490 million yuan, which includes the investment principal and interest from the fund during the investment period [1] - Guizhou Shennong Valley was established in August 2023 with a registered capital of 1 billion yuan [1] - As of March 31, 2025, Guizhou Shennong Valley has total assets of 1.062 billion yuan and net assets of 998 million yuan [1] Group 2: Financial Performance - In 2024, Zhenbaodao achieved revenue of 2.704 billion yuan, a year-on-year decrease of 13.84%, marking the lowest record in five years [2] - In the first quarter of 2025, the company reported a revenue decline of 58.03% to 469 million yuan and a net profit decline of 74.33% to 75.3 million yuan [2] - The decline in revenue and profit is attributed to the postponement of the third batch of national Chinese medicine procurement [2] Group 3: Product Development - On the same day as the acquisition announcement, Zhenbaodao received approval for clinical trials of its Fufang Qinlan Oral Liquid for children aged 4-12 [3] - The pediatric medication sector is experiencing significant policy benefits, and Fufang Qinlan Oral Liquid is positioned as a core product in Zhenbaodao's "anti-viral Chinese medicine matrix" [3] - The company’s total assets reached approximately 12.713 billion yuan by the end of 2024, with a year-on-year growth of 1.98% [3]